Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab

Trial Profile

A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pembrolizumab (Primary) ; UV 1 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Ultimovacs AS
  • Most Recent Events

    • 01 Oct 2019 According to an Ultimovacs AS media release, data were presented at the ESMO 2019.
    • 01 Oct 2019 According to an Ultimovacs AS media release, all formal criteria are fulfilled to start the inclusion of 10 additional patients in this trial. Originally planned 20 patients have been enrolled. all patients are expected to recruited by early 2020.
    • 21 Aug 2019 Planned number of patients changed from 20 to 30, according to an Ultimovacs AS media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top